• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恶性疟原虫 M1 丙氨酰氨基肽酶(PfM1AAP)和 M17 亮氨酰氨基肽酶(PfM17LAP)的生化和细胞特性。

Biochemical and cellular characterisation of the Plasmodium falciparum M1 alanyl aminopeptidase (PfM1AAP) and M17 leucyl aminopeptidase (PfM17LAP).

机构信息

Institute of Parasitology, McGill University, 21111 Lakeshore Road, Sainte-Anne-de-Bellevue, Québec, H9X 3V9, Canada.

School of Biological Sciences, Queen's University Belfast, Belfast, Northern Ireland, UK.

出版信息

Sci Rep. 2021 Feb 3;11(1):2854. doi: 10.1038/s41598-021-82499-4.

DOI:10.1038/s41598-021-82499-4
PMID:33536500
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7858622/
Abstract

The Plasmodium falciparum M1 alanyl aminopeptidase and M17 leucyl aminopeptidase, PfM1AAP and PfM17LAP, are potential targets for novel anti-malarial drug development. Inhibitors of these aminopeptidases have been shown to kill malaria parasites in culture and reduce parasite growth in murine models. The two enzymes may function in the terminal stages of haemoglobin digestion, providing free amino acids for protein synthesis by the rapidly growing intra-erythrocytic parasites. Here we have performed a comparative cellular and biochemical characterisation of the two enzymes. Cell fractionation and immunolocalisation studies reveal that both enzymes are associated with the soluble cytosolic fraction of the parasite, with no evidence that they are present within other compartments, such as the digestive vacuole (DV). Enzyme kinetic studies show that the optimal pH of both enzymes is in the neutral range (pH 7.0-8.0), although PfM1AAP also possesses some activity (< 20%) at the lower pH range of 5.0-5.5. The data supports the proposal that PfM1AAP and PfM17LAP function in the cytoplasm of the parasite, likely in the degradation of haemoglobin-derived peptides generated in the DV and transported to the cytosol.

摘要

疟原虫 falciparum M1 丙氨酰氨基肽酶和 M17 亮氨酰氨基肽酶(PfM1AAP 和 PfM17LAP)是新型抗疟药物开发的潜在靶点。这些氨基肽酶的抑制剂已被证明可以在培养物中杀死疟原虫,并减少鼠模型中的寄生虫生长。这两种酶可能在血红蛋白消化的终末阶段发挥作用,为快速生长的红细胞内寄生虫提供用于蛋白质合成的游离氨基酸。在这里,我们对这两种酶进行了比较细胞和生化特性分析。细胞分级分离和免疫定位研究表明,这两种酶都与寄生虫的可溶性胞质部分相关,没有证据表明它们存在于其他隔间,如消化液泡(DV)中。酶动力学研究表明,两种酶的最佳 pH 值均在中性范围内(pH7.0-8.0),尽管 PfM1AAP 在较低的 pH 值范围(5.0-5.5)下也具有一定的活性(<20%)。这些数据支持了 PfM1AAP 和 PfM17LAP 在寄生虫细胞质中发挥作用的观点,可能在 DV 中产生的血红蛋白衍生肽的降解和运输到细胞质中发挥作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1287/7858622/45b57cc34fc5/41598_2021_82499_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1287/7858622/049044868c95/41598_2021_82499_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1287/7858622/40e15deb7d75/41598_2021_82499_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1287/7858622/0c5fae7407d3/41598_2021_82499_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1287/7858622/2c0d48998d7e/41598_2021_82499_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1287/7858622/b24c622572d5/41598_2021_82499_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1287/7858622/1f03d6c1b6a8/41598_2021_82499_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1287/7858622/8982417d61bf/41598_2021_82499_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1287/7858622/45b57cc34fc5/41598_2021_82499_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1287/7858622/049044868c95/41598_2021_82499_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1287/7858622/40e15deb7d75/41598_2021_82499_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1287/7858622/0c5fae7407d3/41598_2021_82499_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1287/7858622/2c0d48998d7e/41598_2021_82499_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1287/7858622/b24c622572d5/41598_2021_82499_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1287/7858622/1f03d6c1b6a8/41598_2021_82499_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1287/7858622/8982417d61bf/41598_2021_82499_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1287/7858622/45b57cc34fc5/41598_2021_82499_Fig8_HTML.jpg

相似文献

1
Biochemical and cellular characterisation of the Plasmodium falciparum M1 alanyl aminopeptidase (PfM1AAP) and M17 leucyl aminopeptidase (PfM17LAP).恶性疟原虫 M1 丙氨酰氨基肽酶(PfM1AAP)和 M17 亮氨酰氨基肽酶(PfM17LAP)的生化和细胞特性。
Sci Rep. 2021 Feb 3;11(1):2854. doi: 10.1038/s41598-021-82499-4.
2
Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials.恶性疟原虫中性氨肽酶:抗疟药的新靶标。
Trends Biochem Sci. 2010 Jan;35(1):53-61. doi: 10.1016/j.tibs.2009.08.004. Epub 2009 Sep 30.
3
Screening and In Vitro Evaluation of Potential Plasmodium falciparum Leucyl Aminopeptidase Inhibitors.恶性疟原虫亮氨酰氨肽酶潜在抑制剂的筛选及体外评价
Curr Comput Aided Drug Des. 2016;12(4):282-293. doi: 10.2174/1573409912666160722111053.
4
KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.KBE009:一种在乌吉多组分反应衍生的拟肽文库中发现的恶性疟原虫M1氨肽酶的抗疟类贝司他汀抑制剂。
Bioorg Med Chem. 2017 Sep 1;25(17):4628-4636. doi: 10.1016/j.bmc.2017.06.047. Epub 2017 Jul 4.
5
The M18 aspartyl aminopeptidase of the human malaria parasite Plasmodium falciparum.人类疟原虫恶性疟原虫的M18天冬氨酰氨肽酶
J Biol Chem. 2007 Oct 19;282(42):30817-26. doi: 10.1074/jbc.M704938200. Epub 2007 Aug 20.
6
Characterization of the Plasmodium falciparum M17 leucyl aminopeptidase. A protease involved in amino acid regulation with potential for antimalarial drug development.恶性疟原虫M17亮氨酰氨肽酶的特性。一种参与氨基酸调节且具有抗疟药物开发潜力的蛋白酶。
J Biol Chem. 2007 Jan 19;282(3):2069-80. doi: 10.1074/jbc.M609251200. Epub 2006 Nov 15.
7
Chemical target validation studies of aminopeptidase in malaria parasites using alpha-aminoalkylphosphonate and phosphonopeptide inhibitors.使用α-氨基烷基膦酸酯和膦肽抑制剂对疟原虫氨肽酶进行化学靶点验证研究。
Antimicrob Agents Chemother. 2008 Sep;52(9):3221-8. doi: 10.1128/AAC.01327-07. Epub 2008 May 5.
8
Overexpression of leucyl aminopeptidase in Plasmodium falciparum parasites. Target for the antimalarial activity of bestatin.恶性疟原虫中亮氨酰氨肽酶的过表达。贝司他汀抗疟活性的靶点。
J Biol Chem. 2006 Jan 20;281(3):1741-5. doi: 10.1074/jbc.M508955200. Epub 2005 Nov 14.
9
M17 leucine aminopeptidase of the human malaria parasite Plasmodium vivax.间日疟原虫的M17亮氨酸氨肽酶,这是一种人类疟原虫。
Mol Biochem Parasitol. 2010 Mar;170(1):45-8. doi: 10.1016/j.molbiopara.2009.11.003. Epub 2009 Nov 18.
10
Fingerprinting the substrate specificity of M1 and M17 aminopeptidases of human malaria, Plasmodium falciparum.鉴定人疟原虫(Plasmodium falciparum)M1 和 M17 氨肽酶的底物特异性。
PLoS One. 2012;7(2):e31938. doi: 10.1371/journal.pone.0031938. Epub 2012 Feb 16.

引用本文的文献

1
Redox Homeostasis within the Drug-Resistant Malarial Parasite Digestive Vacuole.耐药疟原虫消化泡内的氧化还原稳态
Biochemistry. 2025 May 20;64(10):2247-2261. doi: 10.1021/acs.biochem.4c00750. Epub 2025 May 1.
2
Iron transport pathways in the human malaria parasite revealed by RNA-sequencing.RNA 测序揭示人类疟原虫中的铁运输途径。
Front Cell Infect Microbiol. 2024 Nov 7;14:1480076. doi: 10.3389/fcimb.2024.1480076. eCollection 2024.
3
Chemoproteomics validates selective targeting of M1 alanyl aminopeptidase as an antimalarial strategy.

本文引用的文献

1
K13, the Cytostome, and Artemisinin Resistance.K13、液泡、青蒿素耐药性。
Trends Parasitol. 2020 Jun;36(6):533-544. doi: 10.1016/j.pt.2020.03.006. Epub 2020 Apr 17.
2
Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions.新型人氨肽酶 N 抑制剂:亚结合位点相互作用的发现和优化。
J Med Chem. 2019 Aug 8;62(15):7185-7209. doi: 10.1021/acs.jmedchem.9b00757. Epub 2019 Jul 18.
3
M17 aminopeptidases diversify function by moderating their macromolecular assemblies and active site environment.
化学生物组学验证了 M1 丙氨酰氨基肽酶的选择性靶向作为一种抗疟策略。
Elife. 2024 Jul 8;13:RP92990. doi: 10.7554/eLife.92990.
4
On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity.靶向双重氨肽酶抑制作用提供跨物种抗疟活性。
mBio. 2024 Jun 12;15(6):e0096624. doi: 10.1128/mbio.00966-24. Epub 2024 May 8.
5
Ubenimex combined with Albendazole for the treatment of -induced alveolar echinococcosis in mice.乌苯美司联合阿苯达唑治疗小鼠诱导型肺泡棘球蚴病。
Front Vet Sci. 2024 Mar 15;11:1320308. doi: 10.3389/fvets.2024.1320308. eCollection 2024.
6
An inside out journey: biogenesis, ultrastructure and proteomic characterisation of the ectoparasitic flatworm Sparicotyle chrysophrii extracellular vesicles.从内到外的旅程:寄生性扁形动物栉口吸虫细胞外囊泡的生物发生、超微结构和蛋白质组学特征。
Parasit Vectors. 2024 Apr 3;17(1):175. doi: 10.1186/s13071-024-06257-x.
7
Targeting ME49 TgAPN2: A Bioinformatics Approach for Antiparasitic Drug Discovery.针对 ME49TgAPN2:一种用于抗寄生虫药物发现的生物信息学方法。
Molecules. 2023 Apr 3;28(7):3186. doi: 10.3390/molecules28073186.
8
Genetic and chemical validation of aminopeptidase A-M17 as a drug target in the hemoglobin digestion pathway.遗传和化学验证天冬氨酰蛋白酶 A-M17 作为血红蛋白消化途径中的药物靶点。
Elife. 2022 Sep 13;11:e80813. doi: 10.7554/eLife.80813.
9
The Knock-Down of the Chloroquine Resistance Transporter PfCRT Is Linked to Oligopeptide Handling in Plasmodium falciparum.氯喹耐药转运蛋白 PfCRT 的敲低与恶性疟原虫中的寡肽处理有关。
Microbiol Spectr. 2022 Aug 31;10(4):e0110122. doi: 10.1128/spectrum.01101-22. Epub 2022 Jul 18.
10
Methods Used to Investigate the Digestive Vacuole.研究消化液泡的方法。
Front Cell Infect Microbiol. 2022 Jan 13;11:829823. doi: 10.3389/fcimb.2021.829823. eCollection 2021.
M17 氨肽酶通过调节其大分子组装和活性位点环境来实现功能多样化。
Biochimie. 2019 Nov;166:38-51. doi: 10.1016/j.biochi.2019.01.007. Epub 2019 Jan 14.
4
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.羟肟酸抑制剂提供了对疟原虫 M1 和 M17 氨肽酶的跨物种抑制作用。
J Med Chem. 2019 Jan 24;62(2):622-640. doi: 10.1021/acs.jmedchem.8b01310. Epub 2019 Jan 4.
5
Steered molecular dynamics simulations reveal critical residues for (un)binding of substrates, inhibitors and a product to the malarial M1 aminopeptidase.导向分子动力学模拟揭示了疟原虫 M1 氨肽酶与底物、抑制剂和产物(非)结合的关键残基。
PLoS Comput Biol. 2018 Oct 31;14(10):e1006525. doi: 10.1371/journal.pcbi.1006525. eCollection 2018 Oct.
6
Biochemical characterization of aminopeptidase N2 from Toxoplasma gondii.来自刚地弓形虫的氨肽酶N2的生化特性
J Vet Med Sci. 2017 Aug 18;79(8):1404-1411. doi: 10.1292/jvms.17-0119. Epub 2017 Jul 13.
7
M1 aminopeptidases as drug targets: broad applications or therapeutic niche?M1型氨肽酶作为药物靶点:广泛应用还是治疗利基?
FEBS J. 2017 May;284(10):1473-1488. doi: 10.1111/febs.14009. Epub 2017 Feb 3.
8
Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions.通过优化S1口袋相互作用得到的恶性疟原虫M1和M17氨肽酶的强效双重抑制剂。
Eur J Med Chem. 2016 Mar 3;110:43-64. doi: 10.1016/j.ejmech.2016.01.015. Epub 2016 Jan 13.
9
Haemoglobin degradation underpins the sensitivity of early ring stage Plasmodium falciparum to artemisinins.血红蛋白降解是恶性疟原虫早期环状体阶段对青蒿素敏感的基础。
J Cell Sci. 2016 Jan 15;129(2):406-16. doi: 10.1242/jcs.178830. Epub 2015 Dec 16.
10
X-ray crystal structures of an orally available aminopeptidase inhibitor, Tosedostat, bound to anti-malarial drug targets PfA-M1 and PfA-M17.一种口服可用的氨肽酶抑制剂托西司他与抗疟药物靶点PfA-M1和PfA-M17结合的X射线晶体结构。
Proteins. 2015 Apr;83(4):789-95. doi: 10.1002/prot.24771. Epub 2015 Feb 28.